Núria W. Negrão, PhD | Authors


The Role of Biomarker Testing in Ovarian Cancer

October 17, 2022

There is no single best treatment algorithm for ovarian cancer. Treatment decisions, which become increasingly complex with disease progression, are informed by several patient-specific clinicopathologic parameters and genomic results.

Increased Molecular Understanding Informs Mantle Cell Treatment Choices

October 02, 2022

Traditionally, MCL was dichotomized based on the age of the patient and their ability to tolerate intensive therapy, [but] now we have to take into consideration biological differences across patients that go well beyond age, says Andre H. Goy, MD.